(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Intriguing Social Unesco World Legacy Locales All over The Planet - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3Manual for Picking Coastline Travel
- 4Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- 5Investigating Design and Individual Style: Track down Your Remarkable Look
- Top 15 Web-based Entertainment Stages for Individual Marking
- Can a mammogram help identify heart disease?
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- Couch Styles of 2024: What's Moving
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- Vote In favor of Your Number one Savvy Beds
- NASA shares first photos of Earth taken by Artemis II
